EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development

Simeon Rüdesheim iD, Helena Leonie Hanae Loer, Denise Feick, Fatima Zahra Marok, Laura Maria Fuhr, Dominik Selzer iD, Donato Teutonico, Annika R P Schneider, Juri Solodenko iD, Sebastian Frechen, Maaike van der Lee iD, Dirk Jan A R Moes iD and 3 more

Clinical Pharmacology & Therapeutics · 2025-06 · 117 (6) · 1718-1731

DOI: 10.1002/cpt.3604 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, published online on 2025-02-14. Written by Simeon Rüdesheim and 14 co-authors. Institution: Clinical Pharmacy, Saarland University, Saarbrücken, Germany. Major MEDLINE topics: Cytochrome P-450 CYP2D6, Drug Development, Precision Medicine, Cytochrome P-450 CYP2D6 Inhibitors. Cited 16 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Conducting clinical studies on drug–drug‐gene interactions (DDGIs) and extrapolating the findings into clinical dose recommendations is challenging due to the high complexity of these interactions. Here, physiologically‐based pharmacokinetic (PBPK) modeling networks present a new avenue for exploring such complex scenarios, potentially informing clinical guidelines and handling patient‐specific DDGIs at the bedside. Moreover, they provide an established framework for drug–drug interaction (DDI) submissions to regulatory agencies. The cytochrome P450 (CYP) 2D6 enzyme is particularly prone to DDGIs due to the high prevalence of genetic variation and common use of CYP2D6 inhibiting drugs. In this study, we present a comprehensive PBPK network covering CYP2D6 drug–gene interactions (DGIs), DDIs, and DDGIs. The network covers sensitive and moderate sensitive substrates, and strong and weak inhibitors of CYP2D6 according to the United States Food and Drug Administration (FDA) guidance. For the analyzed CYP2D6 substrates and inhibitors, DD(G)Is mediated by CYP3A4 and P‐glycoprotein were included. Overall, the network comprises 23 compounds and was developed based on 30 DGI, 45 DDI, and seven DDGI studies, covering 32 unique drug combinations. Good predictive performance was demonstrated for all interaction types, as reflected in mean geometric mean fold errors of 1.40, 1.38, and 1.56 for the DD(G)I area under the curve ratios as well as 1.29, 1.43, and 1.60 for DD(G)I maximum plasma concentration ratios. Finally, the presented network was utilized to calculate dose adaptations for CYP2D6 substrates atomoxetine (sensitive) and metoprolol (moderate sensitive) for clinically untested DDGI scenarios, showcasing a potential clinical application of DDGI model networks in the field of model‐informed precision dosing.

Subjects

MeSH terms (MEDLINE)

Cytochrome P-450 CYP2D6Drug DevelopmentPrecision MedicineCytochrome P-450 CYP2D6 InhibitorsHumansDrug InteractionsModels, Biological

Substances

Cytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 Inhibitors

Authors and institutions

  • Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
  • Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Drug Metabolism and Pharmacokinetics, Sanofi R&D, Frankfurt am Main, Germany.
  • Translational Medicine & Early Development, Sanofi R&D, Vitry-sur-Seine, France.
  • Bayer AG, Pharmaceuticals, Research & Development, Model-Informed Drug Development, Leverkusen, Germany.
  • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

ORCID profiles: Simeon Rüdesheim, Dominik Selzer, Juri Solodenko, Maaike van der Lee, Dirk Jan A R Moes, Jesse J Swen, Matthias Schwab, Thorsten Lehr

Cite

APA

Rüdesheim, S., Loer, H. L. H., Feick, D., Marok, F. Z., Fuhr, L. M., Selzer, D., Teutonico, D., Schneider, A. R. P., Solodenko, J., Frechen, S., van der Lee, M., Moes, D. J. A. R., Swen, J. J., Schwab, M., & Lehr, T. (2025). A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development. Clinical Pharmacology & Therapeutics, 117(6), 1718-1731. https://doi.org/10.1002/cpt.3604

Vancouver

Rüdesheim S, Loer HLH, Feick D, Marok FZ, Fuhr LM, Selzer D, et al. A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development. Clinical Pharmacology & Therapeutics. 2025;117(6):1718-1731. doi:10.1002/cpt.3604

BibTeX
@article{Rdesheim2025,
  author = {Rüdesheim, Simeon and Loer, Helena Leonie Hanae and Feick, Denise and Marok, Fatima Zahra and Fuhr, Laura Maria and Selzer, Dominik and Teutonico, Donato and Schneider, Annika R P and Solodenko, Juri and Frechen, Sebastian and van der Lee, Maaike and Moes, Dirk Jan A R and Swen, Jesse J and Schwab, Matthias and Lehr, Thorsten},
  title = {A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {6},
  pages = {1718--1731},
  doi = {10.1002/cpt.3604}
}
Start for free →